Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maluf Fernando Cotait, Pereira Felipe Moraes Toledo, Serrano Uson Pedro Luiz, Bastos Diogo Assed, Rodrigues da Rosa Diogo Augusto, Wiermann Evanius Garcia, Schutz Fábio A, Kater Fábio Roberto, de Oliveira Fernando Nunes Galvão, Marques Monteiro Fernando Sabino, de Pádua Fernando Vidigal, Orlandi Francisco Javier, de Almeida Saito Helena Paes, Ayadi Mouna, Boghikian Pamela Salman, Kopp Ray Manneh, de Carvalho Ricardo Saraiva, de Fogace Rodrigo Nogueira, de Araújo Cavallero Sandro Roberto, Aguiar Sergio, Souza Vinicius Carreira, Sommer Silke Gillessen
Аннотация
METHODS: A total of 24 out of 300 questions addressed staging, treatment, and follow-up for patients with mCSPC both in best-practice settings and resource-limited settings. Responses were compiled and presented in percentage of clinicians supporting each response. Questions had 4-8 options for response.
RESULTS: Recommendations for staging in mCSPC were split but there was consensus that chest x-ray, abdominal and pelvic computed tomography, and bone scan should be used where resources are limited. In both de novo and relapsed low-volume mCSPC, orchiectomy alone in limited resources was favored and in relapsed high-volume disease, androgen deprivation therapy plus docetaxel in limited resources and androgen deprivation therapy plus abiraterone in high-resource settings were consensus. A 3-weekly regimen of docetaxel was consensus among voters. When using abiraterone, a regimen of 1,000 mg plus prednisone 5 mg/d is optimal, but in limited-resource settings, half the panel agreed that abiraterone 250 mg with fatty foods plus prednisone 5 mg/d is acceptable. The panel recommended against the use of osteoclast-targeted therapy to prevent osseous complications. There was consensus that monitoring of patients undergoing systemic treatment should only be conducted in case of prostate-specific antigen elevation or progression-suggestive symptoms.
CONCLUSION: The treatment recommendations for most topics addressed differed between the best-practice setting and resource-limited setting, accentuating the need for high-quality evidence that contemplates the effect of limited resources on the management of mCSPC.